Cargando…
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Certain dietary interventions might improve the therapeutic index of cancer treatments. An alternative to the “drug plus diet” approach is the pharmacological reproduction of the metabolic traits of such diets. Here we explored the impact of adding metformin to an established therapeutic regimen on...
Autores principales: | Cuyàs, Elisabet, Fernández-Arroyo, Salvador, Buxó, Maria, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A., Amillano, Kepa, Domínguez, Severina, Luque, Maria, Morilla, Idoia, Stradella, Agostina, Viñas, Gemma, Cortés, Javier, Verdura, Sara, Brunet, Joan, López-Bonet, Eugeni, Garcia, Margarita, Saidani, Samiha, Joven, Jorge, Martin-Castillo, Begoña, Menendez, Javier A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535060/ https://www.ncbi.nlm.nih.gov/pubmed/31076561 http://dx.doi.org/10.18632/aging.101960 |
Ejemplares similares
-
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2019) -
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer
por: Lopez-Bonet, Eugeni, et al.
Publicado: (2019) -
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
por: Martin-Castillo, Begoña, et al.
Publicado: (2018) -
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015) -
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)